Dr. Dugel is the current president of Iveric Bio and has aided the company in business strategy and developing avacincaptad pegol, a drug that treats geographic atrophy associated with age-related macular degeneration, according to a Jan. 3 news release. He has been with the company since 2020, formerly serving as the company’s executive vice president and has 26 years of experience as a retinal specialist.
“On behalf of the entire board of directors, we are excited to have Pravin join our board during this pivotal time as the company prepares for a potential approval and commercial launch of ACP in geographic atrophy,” Adrienne Graves, PhD, chair of the board of Iveric Bio, said in the release.
